Sorrento Therpt (SRNE)

Nearly a third of SRNE stock's float has been sold short. This sets up a catalyst for a short-term move, but avoid a long-term investment.

Sorrento Therapeutics has seen SRNE stock close between $5.76 and $8.20 in the past month. Here’s why it’s time for investors to be careful. 

SRNE stock fell out of favor as bigger vaccine developers grabbed the headlines but that may change soon.

Sorrento Therapeutics was an early pandemic winner. But as the world closes in on multiple vaccines, SRNE stock looks to be too late.

Investors seeking a longshot coronavirus play continue to eye SRNE stock despite Sorrento Therapeutics' high risk and continued volatility.

Thanks to Sorrento Therapeutics’ all-out pivot to address the Covid-19 pandemic, SRNE stock initially became one of the most popular investments. But as both the vaccine and treatment race tighten, the risks multiply.

SRNE stock has tumbled as larger players have shown progress toward a vaccine. But this isn't just a vaccine play, and the story is far from over.

In this competition, Sorrento is a different beast because it's not just working on a vaccine, it's working on Covid-19 testing, neutralizing antibodies and preventive “shields,” among other products. That's a relevant, robust pipeline, but it hasn't been enough to prevent SRNE stock from sliding 61% from its 52-week high.

If you'd like to wager on a company with a packed clinical pipeline featuring potential Covid-19 treatments, SRNE stock is a great choice.

Sorrento stock continues to be weighed down by the company's inefficacious product pipeline making it an incredibly risky investment.

SRNE stock is a speculative play in the race to develop a Covid-19 therapy

Sorrento stock has lost 50% over the past month. Investors have grown impatient with the company's Covid-19 efforts. Time to buy or sell?

SRNE stock is a purely speculative bet. The company has a deep pipeline of Covid-19 programs. But there is little progress or positive outcome.